Other

Pride Proteomics A/s

Universitè Catholique De Louvain

Zadec Aps

Drugmode Aps

Peter Mose Larsen

Stephen J Fey

Allan E Karlsen

Jorn Nerup

Henrik U Andersen

Flemming Pociot

Ulla Bjerre Christensen

Henning Beck-Nielsen

Johan Louw

Krzysztof Wrzesinski

Jørn Nerup

Kurt Højlund

Inger Byrjalsen

Thomas Sparre

Lizette Joubert

Marc Boutry

Ulla Andrup Jensen

Thais Taaning Johansen

Keld Kjeldsen

Jo Slashedrn Carlsen

Stig Haunso Slashed

Herve Degand

Stephen John Fey

Novel and useful compositions derived from rooibos for treating diabetes are provided. The present invention is particularly concerned with the treatment of Type 2 diabetes. The invention provides a new use for aspalathin and rutin and compositions containing them for use in the prevention and treatment of diabetes. The invention provides an anti-diabetic agent, an anti-diabetic composition containing the anti-diabetic agent, a foodstuff or beverage containing the anti-diabetic agent, a method for preventing or treating diabetes or impaired glucose tolerance, and a method of decreasing blood glucose level. The anti-diabetic agent may be an extract from rooibos (spp.), aspalathin as such or in combination with rutin.

Anti-diabetic extract of rooibos

Endometrium secreted polypeptides are assayed in body fluids to determine the presence of polypeptides of specified pI and MW values that have been found to be regulated in body fluids according to the status of the endometrium, or the presence of hyperplasia or adenocarcinoma.

Biochemical markers of the human endometrium

Provided are protective and deleterious diabetes-mediating proteins and polynucleotides encoding same, transgenic animals expressing a diabetes-mediating protein, drug screening methods for identifying a test compound capable of altering the expression of a diabetes-mediating protein, and methods of preventing or ameliorating diabetes by administering a compound capable of altering the expression of a diabetes-mediating protein.

Diabetes-mediating proteins and therapeutic uses thereof

Determining the expression level of certain diabetes-mediating proteins provides an approach both for diagnosing diabetes and for ascertaining a predisposition for developing diabetes.

Human diabetes-mediating proteins

The present invention relates to the use of naturally occurring compounds and derivatives thereof as markers for predisposition of diabetes related diseases. The invention also relates to a pharmaceutical composition for treatment of the diabetes related diseases.

Proteins in type 2 diabetes

Provided are mammalian secreted and non-secreted diabetes mediating proteins, including protective and deleterious diabetes-mediating proteins, as well as polynucleotides encoding same, drug screening methods for identifying a test compound capable of altering the expression of a diabetes-mediating protein, and methods of preventing or ameliorating diabetes by administering a compound capable of the expression of a diabetes-mediating protein.

Method for diagnosing diabetes in a mammal

A method and apparatus for analyzing images is provided that uses a master composite image, generated by averaging selected images, to analyze and interpret an existing or new image. This significantly reduces the amount of time and operator effort required to interpret an image. The invention also provides for comparison between individual images. The present invention can be used for analyzing gel electrophoresis images to identify new proteins, and to compare gel images to identify changes in proteins.

Method and apparatus for analyzing images

Methods and computer systems are provided for analyzing cell proteomes to characterize proteins that are up- or down-regulated under different conditions, such as under abnormal or compound treated conditions, including drug screening and testing, as well as proteins and encoding or complementary nucleic acids characterized using such methods and computer systems.

Proteome analysis for characterization of up-and down-regulated proteins in biological samples

Markers for organ rejection

Growing community of inventors

Odense S, Denmark

Peter Mose Larsen